- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00807521
Steroid-induced Reduction of Surgical Stress Study (STRESS)
December 16, 2014 updated by: Christa Boer, Amsterdam UMC, location VUmc
Reduction of the Cardiac Proapoptotic Stress Response by Dexamethasone in Patients Undergoing Coronary Artery Bypass Grafting Surgery
The stress response as induced by myocardial cellular damage during cardiac surgery may lead to myocardial stunning and apoptosis, and could therefore impair postoperative patient recovery.
Surgical trauma typically induces the liberation of cytokines.
Some of these cytokines are strongly associated with the initiation of intracellular proapoptotic pathways through activation of tyrosine kinases and integrins.
The latter are known for their deteriorating effects on cardiac function and are strongly involved in cardiac remodeling.
Dexamethasone is typically administered prior to cardiac surgery in order to especially reduce the release of proinflammatory cytokines.
It has however never been investigated whether this additionally reduces proapoptotic signaling in the human heart, thereby eliminating risk factors for the induction of cardiac dysfunction.
In the present study, the investigators therefore aim to investigate whether dexamethasone inhibits proapoptotic pathways in patients undergoing cardiac surgery.
Furthermore, the investigators would like to elucidate whether this proposed effect of dexamethasone is related to the reduction of the stress response in the heart or indirectly by suppression of cytokine release.
For this purpose the investigators will obtain cardiac biopsies and plasma from patients, who are randomly assigned to placebo or dexamethasone treatment and undergo on and off-pump coronary artery bypass grafting (CABG) surgery.
Study Overview
Status
Withdrawn
Intervention / Treatment
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Amsterdam, Netherlands, 1081 HV
- VU University Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients undergoing coronary artery bypass surgery (CABG)
- Age 18-75 years
- Informed consent
Exclusion Criteria:
- Re-operations and emergency operations
- Patient with anemia (Hb < 5.0)
- Emergency operation
- Patients receiving blood transfusions < 3 months before operation
- Insulin depended diabetes mellitus
- Hepatic or renal failure
- Pregnancy
- Use of steroids
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: 2
Placebo control
|
Placebo for dexamethasone
|
|
Active Comparator: 1
High dose bolus of dexamethasone before surgery
|
Single high dose bolus of dexamethasone before surgery
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Expression of p38 in cultured cells and cardiac tissue
Time Frame: One week
|
One week
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Pro-apoptotic signaling, precursor peptides of ANP (proANP), vasopressin (Copeptin), proET-1 and Adrenomedullin (proADM). Age, gender, length, body weight, hematocrit, Hb, leukocytes, surgery time, clamp time, CPB time
Time Frame: One week
|
One week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jan R. de Jong, MD, Amsterdam UMC, location VUmc
- Study Chair: dr. Christa Boer, PhD, Amsterdam UMC, location VUmc
- Principal Investigator: dr. Everaldo M. Redout, PhD, Amsterdam UMC, location VUmc
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2008
Primary Completion (Actual)
December 1, 2010
Study Completion (Actual)
June 1, 2011
Study Registration Dates
First Submitted
December 11, 2008
First Submitted That Met QC Criteria
December 11, 2008
First Posted (Estimate)
December 12, 2008
Study Record Updates
Last Update Posted (Estimate)
December 17, 2014
Last Update Submitted That Met QC Criteria
December 16, 2014
Last Verified
December 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Coronary Disease
- Coronary Stenosis
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Dexamethasone
Other Study ID Numbers
- 08/214
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.